The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting

Inclusion Criteria:

• Participants with prescriptions in deucravacitinib or any biologics as comparator group during the indexing period.
• Participants with at least one confirmed diagnosis of disease code for psoriasis within 12 months prior to the index date.
• Aged 18 years or older at the index date

Exclusion Criteria:

• Participants with prescription in deucravacitinib or any biologics as comparator group prior to the index date.
• Participants with fewer than 12 months of available claim records prior to the index date.
• Participants with no claims record within 1-year after the index date (no visit after the index date).
• Specific for serious infection: Participants who had at least one disease code of hospitalized infection in the 60 days period before the index date.
• Specific for malignancy: Participants who had at least one disease code of malignancy prior to the index date

The study population will include adult patients identified from the Japanese healthcare claims database with psoriasis who have initiated either deucravacitinib or any biologic treatment for psoriasis